Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

Rhythm Pharmaceuticals (RYTM) EBIAT (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed EBIAT for 10 consecutive years, with -$47.5 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 9.73% to -$47.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$196.5 million through Dec 2025, up 24.57% year-over-year, with the annual reading at -$196.5 million for FY2025, 24.58% up from the prior year.
  • EBIAT for Q4 2025 was -$47.5 million at Rhythm Pharmaceuticals, up from -$52.9 million in the prior quarter.
  • The five-year high for EBIAT was $43.8 million in Q1 2021, with the low at -$141.4 million in Q1 2024.
  • Average EBIAT over 5 years is -$45.5 million, with a median of -$44.6 million recorded in 2022.
  • The sharpest move saw EBIAT skyrocketed 228.06% in 2021, then plummeted 220.6% in 2022.
  • Over 5 years, EBIAT stood at -$50.9 million in 2021, then rose by 16.44% to -$42.5 million in 2022, then grew by 2.02% to -$41.6 million in 2023, then decreased by 3.98% to -$43.3 million in 2024, then fell by 9.73% to -$47.5 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$47.5 million, -$52.9 million, and -$46.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.